Methylation Biomarker Panels for Non-Invasive Colorectal Cancer Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for colorectal cancer (CRC) are inadequate, as they are often invasive, costly, and have low sensitivity and specificity, leading to late-stage diagnoses when curative surgical treatment is not possible, and there is a lack of effective non-invasive screening tests.
Innovation Solution
The use of specific methylation patterns of biomarker genes such as P15.INK4b, SST, NPY, JAM2, LAMA1, MDR1, RUNX3, ADHFE1, CNRIP1, GAS7, IRF4, SLIT2, and RERG in body fluids like serum, plasma, or stool for CRC screening, diagnosis, and prognosis, employing techniques like methylation-specific PCR and methylation arrays to assess methylation status.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional diagnostic methods (colonoscopy, biopsy) are used for CRC detection, then diagnostic accuracy can be achieved, but the procedures are invasive, costly, and lead to late-stage diagnoses
Solution Approach 1:
The patent introduces circulating tumor DNA (ctDNA) as an intermediary biomarker that carries epigenetic information from the tumor to accessible body fluids. This mediator allows indirect detection of CRC through non-invasive blood or stool samples, eliminating the need for direct tissue sampling while maintaining diagnostic accuracy through analysis of tumor-specific methylation patterns in ctDNA
Solution Approach 2:
The patent replaces mechanical/invasive diagnostic procedures (colonoscopy with physical examination and biopsy with tissue extraction) with molecular detection methods. By substituting mechanical intervention with biochemical analysis of circulating DNA and its methylation patterns, the system achieves equivalent or superior diagnostic accuracy without physical invasion
2Ease of operation
If traditional biomarkers (CEA, CA19-9) are used for screening, then tests are non-invasive and easy to implement, but sensitivity and specificity are insufficient
Solution Approach 1:
The patent employs a composite biomarker approach by analyzing multiple genes simultaneously (e.g., SEPT9, VIM, B7H3, RASSF1A, GAS6) rather than relying on a single traditional marker. This composite strategy combines the diagnostic signals from multiple tumor-associated genes, creating a synergistic effect that dramatically improves both sensitivity and specificity while maintaining the ease of blood or stool sample collection
Solution Approach 2:
The patent detects epigenetic parameter changes (DNA methylation patterns) rather than relying on protein concentration changes detected by traditional markers. By measuring methylation status at specific CpG sites in tumor-related genes, the system captures tumor-specific molecular alterations that are not detectable by conventional protein-based markers, thereby enhancing measurement precision
3Reliability
If early-stage CRC detection is pursued, then curative treatment opportunities increase, but current methods lack the sensitivity to detect early forms
Solution Approach 1:
The patent extracts and isolates circulating tumor DNA (ctDNA) from the complex background of normal cellular DNA in blood or stool samples. By specifically enriching for tumor-derived DNA fragments through methylation-specific PCR or other targeted approaches, the system can detect even minute amounts of tumor DNA released by early-stage lesions, overcoming the dilution effect and low concentration challenges
Solution Approach 2:
The patent uses DNA methylation patterns as an intermediary signal that amplifies the detectability of early-stage tumors. Even when tumor DNA concentration is extremely low, the presence of abnormal methylation patterns serves as a distinctive molecular signature that can be detected with high sensitivity through specialized assays, enabling early detection before significant tumor burden develops
Data Source
AI summary
The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.